APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cell Therapy CDMO Services

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cell Therapy CDMO Services Market Analysis and Forecast 2026-2032

12 August 2026185 pages

Choose your research edition.

Industry ResearchCell Therapy CDMO Services Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Cell Therapy CDMO Services Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Cell Therapy CDMO Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cell Therapy CDMO Services Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Cell Therapy CDMO Services Market Analysis and Forecast 2026-2032185 pages · $4,950 USD

Market perspective

The global Cell Therapy CDMO Services market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Cell Therapy CDMO Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cell Therapy CDMO Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cell Therapy CDMO Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cell Therapy CDMO Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Cell Therapy CDMO Services include Thermo Fisher Scientific, Wuxi AppTec, Lonza, KBI Biopharma, RoslinCT, Cell and Gene Therapy Catapult, Cell Therapies, Minaris Regenerative Medicine and MEDINET, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Cell Therapy CDMO Services, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cell Therapy CDMO Services, also provides the revenue of main regions and countries. Of the upcoming market potential for Cell Therapy CDMO Services, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cell Therapy CDMO Services revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cell Therapy CDMO Services market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cell Therapy CDMO Services revenue, projected growth trends, production technology, application and end-user industry.

Cell Therapy CDMO Services Segment by Company

Thermo Fisher Scientific

Wuxi AppTec

Lonza

KBI Biopharma

RoslinCT

Cell and Gene Therapy Catapult

Cell Therapies

Minaris Regenerative Medicine

MEDINET

Catalent Biologics

Oxford BioMedica

GenScript

Cell-Easy

SK pharmteco

Charles River Laboratories

AGC Biologics

FUJIFILM Cellular Dynamics

Cell Therapy CDMO Services Segment by Type

Preclinical Stage

Clinical Commercialization Stage

Cell Therapy CDMO Services Segment by Application

Pharmaceutical Company

Research Institute

Cell Therapy CDMO Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell Therapy CDMO Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cell Therapy CDMO Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell Therapy CDMO Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Cell Therapy CDMO Services in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Cell Therapy CDMO Services company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cell Therapy CDMO Services revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cell Therapy CDMO Services Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Preclinical Stage Major Player Table 3. Clinical Commercialization Stage Major Player Table 4. Global Cell Therapy CDMO Services Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Pharmaceutical Company Major Player Table 6. Research Institute Major Player Table 7. Cell Therapy CDMO Services Industry Trends Table 8. Cell Therapy CDMO Services Industry Drivers Table 9. Cell Therapy CDMO Services Industry Opportunities and Challenges Table 10. Cell Therapy CDMO Services Industry Restraints Table 11. Global Cell Therapy CDMO Services Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Cell Therapy CDMO Services Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Cell Therapy CDMO Services Market Share by Region (2021-2026) Table 14. Global Cell Therapy CDMO Services Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Cell Therapy CDMO Services Market Share by Region (2027-2032) Table 16. Global Cell Therapy CDMO Services Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Cell Therapy CDMO Services Revenue Market Share by Players (2021-2026) Table 18. Global Cell Therapy CDMO Services Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Cell Therapy CDMO Services Key Players Headquarters & Area Served Table 20. Global Cell Therapy CDMO Services Players, Product Type & Application Table 21. Global Cell Therapy CDMO Services Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Cell Therapy CDMO Services by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Cell Therapy CDMO Services Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Cell Therapy CDMO Services Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Cell Therapy CDMO Services Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Cell Therapy CDMO Services Revenue Market Share by Type (2021-2026) Table 28. Global Cell Therapy CDMO Services Revenue Market Share by Type (2027-2032) Table 29. Global Cell Therapy CDMO Services Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Cell Therapy CDMO Services Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Cell Therapy CDMO Services Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Cell Therapy CDMO Services Revenue Market Share by Application (2021-2026) Table 33. Global Cell Therapy CDMO Services Revenue Market Share by Application (2027-2032) Table 34. Thermo Fisher Scientific Company Information Table 35. Thermo Fisher Scientific Business Overview Table 36. Thermo Fisher Scientific Cell Therapy CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Thermo Fisher Scientific Cell Therapy CDMO Services Product Portfolio Table 38. Thermo Fisher Scientific Recent Development Table 39. Wuxi AppTec Company Information Table 40. Wuxi AppTec Business Overview Table 41. Wuxi AppTec Cell Therapy CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Wuxi AppTec Cell Therapy CDMO Services Product Portfolio Table 43. Wuxi AppTec Recent Development Table 44. Lonza Company Information Table 45. Lonza Business Overview Table 46. Lonza Cell Therapy CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Lonza Cell Therapy CDMO Services Product Portfolio Table 48. Lonza Recent Development Table 49. KBI Biopharma Company Information Table 50. KBI Biopharma Business Overview Table 51. KBI Biopharma Cell Therapy CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. KBI Biopharma Cell Therapy CDMO Services Product Portfolio Table 53. KBI Biopharma Recent Development Table 54. RoslinCT Company Information Table 55. RoslinCT Business Overview Table 56. RoslinCT Cell Therapy CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. RoslinCT Cell Therapy CDMO Services Product Portfolio Table 58. RoslinCT Recent Development Table 59. Cell and Gene Therapy Catapult Company Information Table 60. Cell and Gene Therapy Catapult Business Overview Table 61. Cell and Gene Therapy Catapult Cell Therapy CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Cell and Gene Therapy Catapult Cell Therapy CDMO Services Product Portfolio Table 63. Cell and Gene Therapy Catapult Recent Development Table 64. Cell Therapies Company Information Table 65. Cell Therapies Business Overview Table 66. Cell Therapies Cell Therapy CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Cell Therapies Cell Therapy CDMO Services Product Portfolio Table 68. Cell Therapies Recent Development Table 69. Minaris Regenerative Medicine Company Information Table 70. Minaris Regenerative Medicine Business Overview Table 71. Minaris Regenerative Medicine Cell Therapy CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Minaris Regenerative Medicine Cell Therapy CDMO Services Product Portfolio Table 73. Minaris Regenerative Medicine Recent Development Table 74. MEDINET Company Information Table 75. MEDINET Business Overview Table 76. MEDINET Cell Therapy CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. MEDINET Cell Therapy CDMO Services Product Portfolio Table 78. MEDINET Recent Development Table 79. Catalent Biologics Company Information Table 80. Catalent Biologics Business Overview Table 81. Catalent Biologics Cell Therapy CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Catalent Biologics Cell Therapy CDMO Services Product Portfolio Table 83. Catalent Biologics Recent Development Table 84. Oxford BioMedica Company Information Table 85. Oxford BioMedica Business Overview Table 86. Oxford BioMedica Cell Therapy CDMO Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Oxford BioMedica Cell Therapy CDMO Services Product Portfolio Table 88. Oxford BioMedica Recent Development Table 89. GenScript Company Information Table 90. GenScript Business Overview Table 91. GenScript Cell Therapy CDMO Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. GenScript Cell Therapy CDMO Services Product Portfolio Table 93. GenScript Recent Development Table 94. Cell-Easy Company Information Table 95. Cell-Easy Business Overview Table 96. Cell-Easy Cell Therapy CDMO Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Cell-Easy Cell Therapy CDMO Services Product Portfolio Table 98. Cell-Easy Recent Development Table 99. SK pharmteco Company Information Table 100. SK pharmteco Business Overview Table 101. SK pharmteco Cell Therapy CDMO Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. SK pharmteco Cell Therapy CDMO Services Product Portfolio Table 103. SK pharmteco Recent Development Table 104. Charles River Laboratories Company Information Table 105. Charles River Laboratories Business Overview Table 106. Charles River Laboratories Cell Therapy CDMO Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Charles River Laboratories Cell Therapy CDMO Services Product Portfolio Table 108. Charles River Laboratories Recent Development Table 109. AGC Biologics Company Information Table 110. AGC Biologics Business Overview Table 111. AGC Biologics Cell Therapy CDMO Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. AGC Biologics Cell Therapy CDMO Services Product Portfolio Table 113. AGC Biologics Recent Development Table 114. FUJIFILM Cellular Dynamics Company Information Table 115. FUJIFILM Cellular Dynamics Business Overview Table 116. FUJIFILM Cellular Dynamics Cell Therapy CDMO Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. FUJIFILM Cellular Dynamics Cell Therapy CDMO Services Product Portfolio Table 118. FUJIFILM Cellular Dynamics Recent Development Table 119. North America Cell Therapy CDMO Services Revenue by Type (2021-2026) & (US$ Million) Table 120. North America Cell Therapy CDMO Services Revenue by Type (2027-2032) & (US$ Million) Table 121. North America Cell Therapy CDMO Services Revenue by Application (2021-2026) & (US$ Million) Table 122. North America Cell Therapy CDMO Services Revenue by Application (2027-2032) & (US$ Million) Table 123. North America Cell Therapy CDMO Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. North America Cell Therapy CDMO Services Revenue by Country (2021-2026) & (US$ Million) Table 125. North America Cell Therapy CDMO Services Revenue by Country (US$ Million) & (2027-2032) Table 126. Europe Cell Therapy CDMO Services Revenue by Type (2021-2026) & (US$ Million) Table 127. Europe Cell Therapy CDMO Services Revenue by Type (2027-2032) & (US$ Million) Table 128. Europe Cell Therapy CDMO Services Revenue by Application (2021-2026) & (US$ Million) Table 129. Europe Cell Therapy CDMO Services Revenue by Application (2027-2032) & (US$ Million) Table 130. Europe Cell Therapy CDMO Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. Europe Cell Therapy CDMO Services Revenue by Country (2021-2026) & (US$ Million) Table 132. Europe Cell Therapy CDMO Services Revenue by Country (US$ Million) & (2027-2032) Table 133. China Cell Therapy CDMO Services Revenue by Type (2021-2026) & (US$ Million) Table 134. China Cell Therapy CDMO Services Revenue by Type (2027-2032) & (US$ Million) Table 135. China Cell Therapy CDMO Services Revenue by Application (2021-2026) & (US$ Million) Table 136. China Cell Therapy CDMO Services Revenue by Application (2027-2032) & (US$ Million) Table 137. Asia Cell Therapy CDMO Services Revenue by Type (2021-2026) & (US$ Million) Table 138. Asia Cell Therapy CDMO Services Revenue by Type (2027-2032) & (US$ Million) Table 139. Asia Cell Therapy CDMO Services Revenue by Application (2021-2026) & (US$ Million) Table 140. Asia Cell Therapy CDMO Services Revenue by Application (2027-2032) & (US$ Million) Table 141. Asia Cell Therapy CDMO Services Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 142. Asia Cell Therapy CDMO Services Revenue by Region (US$ Million) & (2021-2026) Table 143. Asia Cell Therapy CDMO Services Revenue by Region (US$ Million) & (2027-2032) Table 144. SAMEA Cell Therapy CDMO Services Revenue by Type (2021-2026) & (US$ Million) Table 145. SAMEA Cell Therapy CDMO Services Revenue by Type (2027-2032) & (US$ Million) Table 146. SAMEA Cell Therapy CDMO Services Revenue by Application (2021-2026) & (US$ Million) Table 147. SAMEA Cell Therapy CDMO Services Revenue by Application (2027-2032) & (US$ Million) Table 148. SAMEA Cell Therapy CDMO Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. SAMEA Cell Therapy CDMO Services Revenue by Country (2021-2026) & (US$ Million) Table 150. SAMEA Cell Therapy CDMO Services Revenue by Country (US$ Million) & (2027-2032) Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Cell Therapy CDMO Services Image Figure 2. Global Cell Therapy CDMO Services Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cell Therapy CDMO Services Market Size Share 2021 VS 2025 VS 2032 Figure 4. Preclinical Stage Image Figure 5. Clinical Commercialization Stage Image Figure 6. Global Cell Therapy CDMO Services Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Cell Therapy CDMO Services Market Size Share 2021 VS 2025 VS 2032 Figure 8. Pharmaceutical Company Image Figure 9. Research Institute Image Figure 10. Global Cell Therapy CDMO Services Market Size (US$ Million) & (2021-2032) Figure 11. Global Cell Therapy CDMO Services Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Cell Therapy CDMO Services Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Cell Therapy CDMO Services Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Cell Therapy CDMO Services Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Cell Therapy CDMO Services Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Cell Therapy CDMO Services Revenue Market Share by Type (2021-2032) Figure 18. Global Cell Therapy CDMO Services Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Cell Therapy CDMO Services Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Cell Therapy CDMO Services Revenue Market Share by Application (2021-2032) Figure 21. North America Cell Therapy CDMO Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Cell Therapy CDMO Services Revenue Share by Type (2021-2032) Figure 23. North America Cell Therapy CDMO Services Revenue Share by Application (2021-2032) Figure 24. North America Cell Therapy CDMO Services Revenue Share by Country (2021-2032) Figure 25. United States Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Cell Therapy CDMO Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Cell Therapy CDMO Services Revenue Share by Type (2021-2032) Figure 30. Europe Cell Therapy CDMO Services Revenue Share by Application (2021-2032) Figure 31. Europe Cell Therapy CDMO Services Revenue Share by Country (2021-2032) Figure 32. Germany Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Cell Therapy CDMO Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Cell Therapy CDMO Services Revenue Share by Type (2021-2032) Figure 42. China Cell Therapy CDMO Services Revenue Share by Application (2021-2032) Figure 43. Asia Cell Therapy CDMO Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Cell Therapy CDMO Services Revenue Share by Type (2021-2032) Figure 45. Asia Cell Therapy CDMO Services Revenue Share by Application (2021-2032) Figure 46. Asia Cell Therapy CDMO Services Revenue Share by Region (2021-2032) Figure 47. Japan Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Cell Therapy CDMO Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Cell Therapy CDMO Services Revenue Share by Type (2021-2032) Figure 55. SAMEA Cell Therapy CDMO Services Revenue Share by Application (2021-2032) Figure 56. SAMEA Cell Therapy CDMO Services Revenue Share by Country (2021-2032) Figure 57. Brazil Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Cell Therapy CDMO Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Preclinical Stage
  • Clinical Commercialization Stage
Applications
  • Pharmaceutical Company
  • Research Institute
Companies covered
  • Thermo Fisher Scientific
  • Wuxi AppTec
  • Lonza
  • KBI Biopharma
  • RoslinCT
  • Cell and Gene Therapy Catapult
  • Cell Therapies
  • Minaris Regenerative Medicine
  • MEDINET
  • Catalent Biologics
  • Oxford BioMedica
  • GenScript
  • Cell-Easy
  • SK pharmteco
  • Charles River Laboratories
  • AGC Biologics
  • FUJIFILM Cellular Dynamics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cell Therapy CDMO Services Market by Type
  3. 1.2.1 Global Cell Therapy CDMO Services Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Preclinical Stage
  5. 1.2.3 Clinical Commercialization Stage
  6. 1.3 Cell Therapy CDMO Services Market by Application
  7. 1.3.1 Global Cell Therapy CDMO Services Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Pharmaceutical Company
  9. 1.3.3 Research Institute
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Cell Therapy CDMO Services Market Dynamics
  1. 2.1 Cell Therapy CDMO Services Industry Trends
  2. 2.2 Cell Therapy CDMO Services Industry Drivers
  3. 2.3 Cell Therapy CDMO Services Industry Opportunities and Challenges
  4. 2.4 Cell Therapy CDMO Services Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Cell Therapy CDMO Services Market Perspective (2021-2032)
  2. 3.2 Global Cell Therapy CDMO Services Growth Trends by Region
  3. 3.2.1 Global Cell Therapy CDMO Services Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cell Therapy CDMO Services Market Size by Region (2021-2026)
  5. 3.2.3 Global Cell Therapy CDMO Services Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Cell Therapy CDMO Services Revenue by Players
  2. 4.1.1 Global Cell Therapy CDMO Services Revenue by Players (2021-2026)
  3. 4.1.2 Global Cell Therapy CDMO Services Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Cell Therapy CDMO Services Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cell Therapy CDMO Services Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Cell Therapy CDMO Services Key Players Headquarters & Area Served
  7. 4.4 Global Cell Therapy CDMO Services Players, Product Type & Application
  8. 4.5 Global Cell Therapy CDMO Services Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Cell Therapy CDMO Services Market CR5 and HHI
  11. 4.6.3 2025 Cell Therapy CDMO Services Tier 1, Tier 2, and Tier 3
5 Cell Therapy CDMO Services Market Size by Type
  1. 5.1 Global Cell Therapy CDMO Services Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Cell Therapy CDMO Services Revenue by Type (2021-2032)
  3. 5.3 Global Cell Therapy CDMO Services Revenue Market Share by Type (2021-2032)
6 Cell Therapy CDMO Services Market Size by Application
  1. 6.1 Global Cell Therapy CDMO Services Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Cell Therapy CDMO Services Revenue by Application (2021-2032)
  3. 6.3 Global Cell Therapy CDMO Services Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Thermo Fisher Scientific
  2. 7.1.1 Thermo Fisher Scientific Company Information
  3. 7.1.2 Thermo Fisher Scientific Business Overview
  4. 7.1.3 Thermo Fisher Scientific Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Thermo Fisher Scientific Cell Therapy CDMO Services Product Portfolio
  6. 7.1.5 Thermo Fisher Scientific Recent Developments
  7. 7.2 Wuxi AppTec
  8. 7.2.1 Wuxi AppTec Company Information
  9. 7.2.2 Wuxi AppTec Business Overview
  10. 7.2.3 Wuxi AppTec Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Wuxi AppTec Cell Therapy CDMO Services Product Portfolio
  12. 7.2.5 Wuxi AppTec Recent Developments
  13. 7.3 Lonza
  14. 7.3.1 Lonza Company Information
  15. 7.3.2 Lonza Business Overview
  16. 7.3.3 Lonza Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Lonza Cell Therapy CDMO Services Product Portfolio
  18. 7.3.5 Lonza Recent Developments
  19. 7.4 KBI Biopharma
  20. 7.4.1 KBI Biopharma Company Information
  21. 7.4.2 KBI Biopharma Business Overview
  22. 7.4.3 KBI Biopharma Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  23. 7.4.4 KBI Biopharma Cell Therapy CDMO Services Product Portfolio
  24. 7.4.5 KBI Biopharma Recent Developments
  25. 7.5 RoslinCT
  26. 7.5.1 RoslinCT Company Information
  27. 7.5.2 RoslinCT Business Overview
  28. 7.5.3 RoslinCT Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  29. 7.5.4 RoslinCT Cell Therapy CDMO Services Product Portfolio
  30. 7.5.5 RoslinCT Recent Developments
  31. 7.6 Cell and Gene Therapy Catapult
  32. 7.6.1 Cell and Gene Therapy Catapult Company Information
  33. 7.6.2 Cell and Gene Therapy Catapult Business Overview
  34. 7.6.3 Cell and Gene Therapy Catapult Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Cell and Gene Therapy Catapult Cell Therapy CDMO Services Product Portfolio
  36. 7.6.5 Cell and Gene Therapy Catapult Recent Developments
  37. 7.7 Cell Therapies
  38. 7.7.1 Cell Therapies Company Information
  39. 7.7.2 Cell Therapies Business Overview
  40. 7.7.3 Cell Therapies Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Cell Therapies Cell Therapy CDMO Services Product Portfolio
  42. 7.7.5 Cell Therapies Recent Developments
  43. 7.8 Minaris Regenerative Medicine
  44. 7.8.1 Minaris Regenerative Medicine Company Information
  45. 7.8.2 Minaris Regenerative Medicine Business Overview
  46. 7.8.3 Minaris Regenerative Medicine Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Minaris Regenerative Medicine Cell Therapy CDMO Services Product Portfolio
  48. 7.8.5 Minaris Regenerative Medicine Recent Developments
  49. 7.9 MEDINET
  50. 7.9.1 MEDINET Company Information
  51. 7.9.2 MEDINET Business Overview
  52. 7.9.3 MEDINET Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  53. 7.9.4 MEDINET Cell Therapy CDMO Services Product Portfolio
  54. 7.9.5 MEDINET Recent Developments
  55. 7.10 Catalent Biologics
  56. 7.10.1 Catalent Biologics Company Information
  57. 7.10.2 Catalent Biologics Business Overview
  58. 7.10.3 Catalent Biologics Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Catalent Biologics Cell Therapy CDMO Services Product Portfolio
  60. 7.10.5 Catalent Biologics Recent Developments
  61. 7.11 Oxford BioMedica
  62. 7.11.1 Oxford BioMedica Company Information
  63. 7.11.2 Oxford BioMedica Business Overview
  64. 7.11.3 Oxford BioMedica Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Oxford BioMedica Cell Therapy CDMO Services Product Portfolio
  66. 7.11.5 Oxford BioMedica Recent Developments
  67. 7.12 GenScript
  68. 7.12.1 GenScript Company Information
  69. 7.12.2 GenScript Business Overview
  70. 7.12.3 GenScript Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  71. 7.12.4 GenScript Cell Therapy CDMO Services Product Portfolio
  72. 7.12.5 GenScript Recent Developments
  73. 7.13 Cell-Easy
  74. 7.13.1 Cell-Easy Company Information
  75. 7.13.2 Cell-Easy Business Overview
  76. 7.13.3 Cell-Easy Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Cell-Easy Cell Therapy CDMO Services Product Portfolio
  78. 7.13.5 Cell-Easy Recent Developments
  79. 7.14 SK pharmteco
  80. 7.14.1 SK pharmteco Company Information
  81. 7.14.2 SK pharmteco Business Overview
  82. 7.14.3 SK pharmteco Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  83. 7.14.4 SK pharmteco Cell Therapy CDMO Services Product Portfolio
  84. 7.14.5 SK pharmteco Recent Developments
  85. 7.15 Charles River Laboratories
  86. 7.15.1 Charles River Laboratories Company Information
  87. 7.15.2 Charles River Laboratories Business Overview
  88. 7.15.3 Charles River Laboratories Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Charles River Laboratories Cell Therapy CDMO Services Product Portfolio
  90. 7.15.5 Charles River Laboratories Recent Developments
  91. 7.16 AGC Biologics
  92. 7.16.1 AGC Biologics Company Information
  93. 7.16.2 AGC Biologics Business Overview
  94. 7.16.3 AGC Biologics Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  95. 7.16.4 AGC Biologics Cell Therapy CDMO Services Product Portfolio
  96. 7.16.5 AGC Biologics Recent Developments
  97. 7.17 FUJIFILM Cellular Dynamics
  98. 7.17.1 FUJIFILM Cellular Dynamics Company Information
  99. 7.17.2 FUJIFILM Cellular Dynamics Business Overview
  100. 7.17.3 FUJIFILM Cellular Dynamics Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
  101. 7.17.4 FUJIFILM Cellular Dynamics Cell Therapy CDMO Services Product Portfolio
  102. 7.17.5 FUJIFILM Cellular Dynamics Recent Developments
8 North America
  1. 8.1 North America Cell Therapy CDMO Services Revenue (2021-2032)
  2. 8.2 North America Cell Therapy CDMO Services Revenue by Type (2021-2032)
  3. 8.2.1 North America Cell Therapy CDMO Services Revenue by Type (2021-2026)
  4. 8.2.2 North America Cell Therapy CDMO Services Revenue by Type (2027-2032)
  5. 8.3 North America Cell Therapy CDMO Services Revenue Share by Type (2021-2032)
  6. 8.4 North America Cell Therapy CDMO Services Revenue by Application (2021-2032)
  7. 8.4.1 North America Cell Therapy CDMO Services Revenue by Application (2021-2026)
  8. 8.4.2 North America Cell Therapy CDMO Services Revenue by Application (2027-2032)
  9. 8.5 North America Cell Therapy CDMO Services Revenue Share by Application (2021-2032)
  10. 8.6 North America Cell Therapy CDMO Services Revenue by Country
  11. 8.6.1 North America Cell Therapy CDMO Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Cell Therapy CDMO Services Revenue by Country (2021-2026)
  13. 8.6.3 North America Cell Therapy CDMO Services Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Cell Therapy CDMO Services Revenue (2021-2032)
  2. 9.2 Europe Cell Therapy CDMO Services Revenue by Type (2021-2032)
  3. 9.2.1 Europe Cell Therapy CDMO Services Revenue by Type (2021-2026)
  4. 9.2.2 Europe Cell Therapy CDMO Services Revenue by Type (2027-2032)
  5. 9.3 Europe Cell Therapy CDMO Services Revenue Share by Type (2021-2032)
  6. 9.4 Europe Cell Therapy CDMO Services Revenue by Application (2021-2032)
  7. 9.4.1 Europe Cell Therapy CDMO Services Revenue by Application (2021-2026)
  8. 9.4.2 Europe Cell Therapy CDMO Services Revenue by Application (2027-2032)
  9. 9.5 Europe Cell Therapy CDMO Services Revenue Share by Application (2021-2032)
  10. 9.6 Europe Cell Therapy CDMO Services Revenue by Country
  11. 9.6.1 Europe Cell Therapy CDMO Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Cell Therapy CDMO Services Revenue by Country (2021-2026)
  13. 9.6.3 Europe Cell Therapy CDMO Services Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Cell Therapy CDMO Services Revenue (2021-2032)
  2. 10.2 China Cell Therapy CDMO Services Revenue by Type (2021-2032)
  3. 10.2.1 China Cell Therapy CDMO Services Revenue by Type (2021-2026)
  4. 10.2.2 China Cell Therapy CDMO Services Revenue by Type (2027-2032)
  5. 10.3 China Cell Therapy CDMO Services Revenue Share by Type (2021-2032)
  6. 10.4 China Cell Therapy CDMO Services Revenue by Application (2021-2032)
  7. 10.4.1 China Cell Therapy CDMO Services Revenue by Application (2021-2026)
  8. 10.4.2 China Cell Therapy CDMO Services Revenue by Application (2027-2032)
  9. 10.5 China Cell Therapy CDMO Services Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cell Therapy CDMO Services Revenue (2021-2032)
  2. 11.2 Asia Cell Therapy CDMO Services Revenue by Type (2021-2032)
  3. 11.2.1 Asia Cell Therapy CDMO Services Revenue by Type (2021-2026)
  4. 11.2.2 Asia Cell Therapy CDMO Services Revenue by Type (2027-2032)
  5. 11.3 Asia Cell Therapy CDMO Services Revenue Share by Type (2021-2032)
  6. 11.4 Asia Cell Therapy CDMO Services Revenue by Application (2021-2032)
  7. 11.4.1 Asia Cell Therapy CDMO Services Revenue by Application (2021-2026)
  8. 11.4.2 Asia Cell Therapy CDMO Services Revenue by Application (2027-2032)
  9. 11.5 Asia Cell Therapy CDMO Services Revenue Share by Application (2021-2032)
  10. 11.6 Asia Cell Therapy CDMO Services Revenue by Country
  11. 11.6.1 Asia Cell Therapy CDMO Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Cell Therapy CDMO Services Revenue by Country (2021-2026)
  13. 11.6.3 Asia Cell Therapy CDMO Services Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cell Therapy CDMO Services Revenue (2021-2032)
  2. 12.2 SAMEA Cell Therapy CDMO Services Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Cell Therapy CDMO Services Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Cell Therapy CDMO Services Revenue by Type (2027-2032)
  5. 12.3 SAMEA Cell Therapy CDMO Services Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Cell Therapy CDMO Services Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Cell Therapy CDMO Services Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Cell Therapy CDMO Services Revenue by Application (2027-2032)
  9. 12.5 SAMEA Cell Therapy CDMO Services Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Cell Therapy CDMO Services Revenue by Country
  11. 12.6.1 SAMEA Cell Therapy CDMO Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Cell Therapy CDMO Services Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Cell Therapy CDMO Services Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst